Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women

S. M. Anderson, N. Shah, W. S. Evans, J. T. Patrie, C. Y. Bowers, Johannes D Veldhuis

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Estrogen is a prominent stimulus to GH secretion throughout the human life span, albeit via neuroendocrine mechanisms that are incompletely defined. Here, we test the hypothesis that estradiol replacement in postmenopausal women enhances the responsiveness of the hypothalamo-pituitary unit to the GH-releasing effect of GH-releasing peptide-2 (GHRP-2). GHRP-2 is a potent and selective synthetic hexapeptide capable of activating an endogenous GHRP receptor/effector pathway, for which a 3Ser-octanoylated 28-amino acid ligand was cloned recently. To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17β-estradiol (E 2) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design. The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 μg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting. Serum GH concentrations were determined in blood sampled every 10 min using an ultrasensitive chemiluminescence assay and analyzed by multiparameter deconvolution to calculate the summed mass of GH secreted during the 2-h interval after bolus GHRP-2 infusion. Logarithmically transformed secretory responses were compared across the different dosages of infused GHRP-2 by two-way repeated measures ANOVA. Estradiol replacement increased the global mean (±SEM) serum E 2 concentration from 15 ± 0.8 to 470 ± 17 pg/mL (55 ± 2.9 to 1725 ± 62 pmol/L; P = 0.004) and lowered insulin-like growth factor I levels by approximately 27% (P = 0.087). Administration or E 2 elevated the geometric mean basal (saline-infused) GH secretory burst mass by 2.1-fold (95% confidence interval, 1.4- to 3.1-fold) compared with placebo ingestion (geometric mean ratios; P < 0.001). E 2 exposure enhanced the efficacy of the highest GHRP-2 dose tested (3 μg/kg) by 2.1-fold (1.3- to 3.3-fold; P = 0.010). Compared with the effect of placebo and saline, E 2 combined with the highest dose of GHRP-2 stimulated GH secretory burst mass by a total of 31-fold (24- to 41-fold; P < 0.001). Random coefficient regression analysis of the relationship between the logarithm of GHRP-2 dose and GH secretory burst mass revealed that E 2 significantly augmented the amount of GH secreted per unit GHRP-2 dose (E 2, 16.6 ± 1.8 slope units; placebo, 10.1 ± 1.4 slope units; P = 0.03). Although the global mean endogenous GH half-life did not differ between the E 2 and placebo sessions (E 2, 18 ± 0.6 min; placebo, 17 ± 0.5 min), GH half-life varied directly with dose of GHRP-2 (and, hence, the mean serum GH concentration) in both the E 2 and placebo sessions (test of zero slope hypothesis, P = 0.0018). The deconvolved GH secretory burst peaked within 8-13 min of the bolus iv injection of GHRP-2, and this latency was not altered by E 2. Based on a mixed effects analysis of covariance model, GHRP-2 dose and E 2, but not the plasma insulin-like growth factor I concentration, determined the magnitude of the GH secretory response (P < 0.001). We conclude that short-term oral E 2 repletion in postmenopausal women selectively augments GH secretory pulse mass, enhances the steepness of the GHRP-2 dose-GH secretory response relationship (greater sensitivity), and heightens the maximal GH secretory response to the highest dose of GHRP-2 tested (greater efficacy). These data point to a facilitative interaction between E 2 and the GHRP receptor/effector pathway in driving the mass of GH secreted per burst.

Original languageEnglish (US)
Pages (from-to)551-560
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume86
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Growth Hormone
Estradiol
Peptides
Placebos
Estrogens
gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide
Insulin-Like Growth Factor I
Half-Life
Serum
Blood
Placebo Effect
Luminescence
Chemiluminescence
Cross-Over Studies
Deconvolution
Analysis of variance (ANOVA)
Fasting
Analysis of Variance
Regression analysis
Eating

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women. / Anderson, S. M.; Shah, N.; Evans, W. S.; Patrie, J. T.; Bowers, C. Y.; Veldhuis, Johannes D.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 86, No. 2, 2001, p. 551-560.

Research output: Contribution to journalArticle

@article{1f9b5ac0b04a46d4a6f319e48123c126,
title = "Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women",
abstract = "Estrogen is a prominent stimulus to GH secretion throughout the human life span, albeit via neuroendocrine mechanisms that are incompletely defined. Here, we test the hypothesis that estradiol replacement in postmenopausal women enhances the responsiveness of the hypothalamo-pituitary unit to the GH-releasing effect of GH-releasing peptide-2 (GHRP-2). GHRP-2 is a potent and selective synthetic hexapeptide capable of activating an endogenous GHRP receptor/effector pathway, for which a 3Ser-octanoylated 28-amino acid ligand was cloned recently. To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17β-estradiol (E 2) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design. The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 μg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting. Serum GH concentrations were determined in blood sampled every 10 min using an ultrasensitive chemiluminescence assay and analyzed by multiparameter deconvolution to calculate the summed mass of GH secreted during the 2-h interval after bolus GHRP-2 infusion. Logarithmically transformed secretory responses were compared across the different dosages of infused GHRP-2 by two-way repeated measures ANOVA. Estradiol replacement increased the global mean (±SEM) serum E 2 concentration from 15 ± 0.8 to 470 ± 17 pg/mL (55 ± 2.9 to 1725 ± 62 pmol/L; P = 0.004) and lowered insulin-like growth factor I levels by approximately 27{\%} (P = 0.087). Administration or E 2 elevated the geometric mean basal (saline-infused) GH secretory burst mass by 2.1-fold (95{\%} confidence interval, 1.4- to 3.1-fold) compared with placebo ingestion (geometric mean ratios; P < 0.001). E 2 exposure enhanced the efficacy of the highest GHRP-2 dose tested (3 μg/kg) by 2.1-fold (1.3- to 3.3-fold; P = 0.010). Compared with the effect of placebo and saline, E 2 combined with the highest dose of GHRP-2 stimulated GH secretory burst mass by a total of 31-fold (24- to 41-fold; P < 0.001). Random coefficient regression analysis of the relationship between the logarithm of GHRP-2 dose and GH secretory burst mass revealed that E 2 significantly augmented the amount of GH secreted per unit GHRP-2 dose (E 2, 16.6 ± 1.8 slope units; placebo, 10.1 ± 1.4 slope units; P = 0.03). Although the global mean endogenous GH half-life did not differ between the E 2 and placebo sessions (E 2, 18 ± 0.6 min; placebo, 17 ± 0.5 min), GH half-life varied directly with dose of GHRP-2 (and, hence, the mean serum GH concentration) in both the E 2 and placebo sessions (test of zero slope hypothesis, P = 0.0018). The deconvolved GH secretory burst peaked within 8-13 min of the bolus iv injection of GHRP-2, and this latency was not altered by E 2. Based on a mixed effects analysis of covariance model, GHRP-2 dose and E 2, but not the plasma insulin-like growth factor I concentration, determined the magnitude of the GH secretory response (P < 0.001). We conclude that short-term oral E 2 repletion in postmenopausal women selectively augments GH secretory pulse mass, enhances the steepness of the GHRP-2 dose-GH secretory response relationship (greater sensitivity), and heightens the maximal GH secretory response to the highest dose of GHRP-2 tested (greater efficacy). These data point to a facilitative interaction between E 2 and the GHRP receptor/effector pathway in driving the mass of GH secreted per burst.",
author = "Anderson, {S. M.} and N. Shah and Evans, {W. S.} and Patrie, {J. T.} and Bowers, {C. Y.} and Veldhuis, {Johannes D}",
year = "2001",
doi = "10.1210/jc.86.2.551",
language = "English (US)",
volume = "86",
pages = "551--560",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women

AU - Anderson, S. M.

AU - Shah, N.

AU - Evans, W. S.

AU - Patrie, J. T.

AU - Bowers, C. Y.

AU - Veldhuis, Johannes D

PY - 2001

Y1 - 2001

N2 - Estrogen is a prominent stimulus to GH secretion throughout the human life span, albeit via neuroendocrine mechanisms that are incompletely defined. Here, we test the hypothesis that estradiol replacement in postmenopausal women enhances the responsiveness of the hypothalamo-pituitary unit to the GH-releasing effect of GH-releasing peptide-2 (GHRP-2). GHRP-2 is a potent and selective synthetic hexapeptide capable of activating an endogenous GHRP receptor/effector pathway, for which a 3Ser-octanoylated 28-amino acid ligand was cloned recently. To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17β-estradiol (E 2) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design. The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 μg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting. Serum GH concentrations were determined in blood sampled every 10 min using an ultrasensitive chemiluminescence assay and analyzed by multiparameter deconvolution to calculate the summed mass of GH secreted during the 2-h interval after bolus GHRP-2 infusion. Logarithmically transformed secretory responses were compared across the different dosages of infused GHRP-2 by two-way repeated measures ANOVA. Estradiol replacement increased the global mean (±SEM) serum E 2 concentration from 15 ± 0.8 to 470 ± 17 pg/mL (55 ± 2.9 to 1725 ± 62 pmol/L; P = 0.004) and lowered insulin-like growth factor I levels by approximately 27% (P = 0.087). Administration or E 2 elevated the geometric mean basal (saline-infused) GH secretory burst mass by 2.1-fold (95% confidence interval, 1.4- to 3.1-fold) compared with placebo ingestion (geometric mean ratios; P < 0.001). E 2 exposure enhanced the efficacy of the highest GHRP-2 dose tested (3 μg/kg) by 2.1-fold (1.3- to 3.3-fold; P = 0.010). Compared with the effect of placebo and saline, E 2 combined with the highest dose of GHRP-2 stimulated GH secretory burst mass by a total of 31-fold (24- to 41-fold; P < 0.001). Random coefficient regression analysis of the relationship between the logarithm of GHRP-2 dose and GH secretory burst mass revealed that E 2 significantly augmented the amount of GH secreted per unit GHRP-2 dose (E 2, 16.6 ± 1.8 slope units; placebo, 10.1 ± 1.4 slope units; P = 0.03). Although the global mean endogenous GH half-life did not differ between the E 2 and placebo sessions (E 2, 18 ± 0.6 min; placebo, 17 ± 0.5 min), GH half-life varied directly with dose of GHRP-2 (and, hence, the mean serum GH concentration) in both the E 2 and placebo sessions (test of zero slope hypothesis, P = 0.0018). The deconvolved GH secretory burst peaked within 8-13 min of the bolus iv injection of GHRP-2, and this latency was not altered by E 2. Based on a mixed effects analysis of covariance model, GHRP-2 dose and E 2, but not the plasma insulin-like growth factor I concentration, determined the magnitude of the GH secretory response (P < 0.001). We conclude that short-term oral E 2 repletion in postmenopausal women selectively augments GH secretory pulse mass, enhances the steepness of the GHRP-2 dose-GH secretory response relationship (greater sensitivity), and heightens the maximal GH secretory response to the highest dose of GHRP-2 tested (greater efficacy). These data point to a facilitative interaction between E 2 and the GHRP receptor/effector pathway in driving the mass of GH secreted per burst.

AB - Estrogen is a prominent stimulus to GH secretion throughout the human life span, albeit via neuroendocrine mechanisms that are incompletely defined. Here, we test the hypothesis that estradiol replacement in postmenopausal women enhances the responsiveness of the hypothalamo-pituitary unit to the GH-releasing effect of GH-releasing peptide-2 (GHRP-2). GHRP-2 is a potent and selective synthetic hexapeptide capable of activating an endogenous GHRP receptor/effector pathway, for which a 3Ser-octanoylated 28-amino acid ligand was cloned recently. To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17β-estradiol (E 2) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design. The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 μg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting. Serum GH concentrations were determined in blood sampled every 10 min using an ultrasensitive chemiluminescence assay and analyzed by multiparameter deconvolution to calculate the summed mass of GH secreted during the 2-h interval after bolus GHRP-2 infusion. Logarithmically transformed secretory responses were compared across the different dosages of infused GHRP-2 by two-way repeated measures ANOVA. Estradiol replacement increased the global mean (±SEM) serum E 2 concentration from 15 ± 0.8 to 470 ± 17 pg/mL (55 ± 2.9 to 1725 ± 62 pmol/L; P = 0.004) and lowered insulin-like growth factor I levels by approximately 27% (P = 0.087). Administration or E 2 elevated the geometric mean basal (saline-infused) GH secretory burst mass by 2.1-fold (95% confidence interval, 1.4- to 3.1-fold) compared with placebo ingestion (geometric mean ratios; P < 0.001). E 2 exposure enhanced the efficacy of the highest GHRP-2 dose tested (3 μg/kg) by 2.1-fold (1.3- to 3.3-fold; P = 0.010). Compared with the effect of placebo and saline, E 2 combined with the highest dose of GHRP-2 stimulated GH secretory burst mass by a total of 31-fold (24- to 41-fold; P < 0.001). Random coefficient regression analysis of the relationship between the logarithm of GHRP-2 dose and GH secretory burst mass revealed that E 2 significantly augmented the amount of GH secreted per unit GHRP-2 dose (E 2, 16.6 ± 1.8 slope units; placebo, 10.1 ± 1.4 slope units; P = 0.03). Although the global mean endogenous GH half-life did not differ between the E 2 and placebo sessions (E 2, 18 ± 0.6 min; placebo, 17 ± 0.5 min), GH half-life varied directly with dose of GHRP-2 (and, hence, the mean serum GH concentration) in both the E 2 and placebo sessions (test of zero slope hypothesis, P = 0.0018). The deconvolved GH secretory burst peaked within 8-13 min of the bolus iv injection of GHRP-2, and this latency was not altered by E 2. Based on a mixed effects analysis of covariance model, GHRP-2 dose and E 2, but not the plasma insulin-like growth factor I concentration, determined the magnitude of the GH secretory response (P < 0.001). We conclude that short-term oral E 2 repletion in postmenopausal women selectively augments GH secretory pulse mass, enhances the steepness of the GHRP-2 dose-GH secretory response relationship (greater sensitivity), and heightens the maximal GH secretory response to the highest dose of GHRP-2 tested (greater efficacy). These data point to a facilitative interaction between E 2 and the GHRP receptor/effector pathway in driving the mass of GH secreted per burst.

UR - http://www.scopus.com/inward/record.url?scp=0035095289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035095289&partnerID=8YFLogxK

U2 - 10.1210/jc.86.2.551

DO - 10.1210/jc.86.2.551

M3 - Article

VL - 86

SP - 551

EP - 560

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -